Rxo (RXO) Other Non-Current Liabilities (2021 - 2026)

Rxo (RXO) has reported Other Non-Current Liabilities for 6 consecutive years, with $65.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 7.14% year-over-year to $65.0 million; the trailing twelve-month figure through Jun 2026 stood at $65.0 million (down 7.14% YoY), and the FY2025 full-year result was $69.0 million, down 16.87% from the prior year.
• Other Non-Current Liabilities rose to $65.0 million in Q2 2026 per RXO's latest filing, from $63.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $88.0 million in Q1 2025 and bottomed at $36.0 million in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $55.3 million across 5 years, with a median of $52.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities soared 114.63% in 2025, then retreated 28.41% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $40.0 million in 2022, then changed by 0.0% to $40.0 million in 2023, then jumped by 107.5% to $83.0 million in 2024, then retreated by 16.87% to $69.0 million in 2025, then decreased by 5.8% to $65.0 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $65.0 million, $63.0 million, and $69.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.